Category: Psychedelic Bulletin - Page 16 - Psychedelic Alpha

Read more about the article Psychedelic Bulletin: atai IPOs on Nasdaq; Cybin to Target Anxiety Indications; Next Steps for California Decrim. Bill

Psychedelic Bulletin: atai IPOs on Nasdaq; Cybin to Target Anxiety Indications; Next Steps for California Decrim. Bill

Post published:June 18, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: MindMed CEO Steps Down; Atai Targets $2.3bn Valuation

Psychedelic Bulletin: MindMed CEO Steps Down; Atai Targets $2.3bn Valuation

Post published:June 11, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Poll Shows Support for Psilocybin in the UK; Psychedelics-tinged ETF Launches on NYSE; Patents Make Headlines

Psychedelic Bulletin: Poll Shows Support for Psilocybin in the UK; Psychedelics-tinged ETF Launches on NYSE; Patents Make Headlines

Post published:June 4, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: COMPASS Pathways’ 4th Patent; MagicMed to Be Acquired; MindMed Insider Selling

Psychedelic Bulletin: COMPASS Pathways’ 4th Patent; MagicMed to Be Acquired; MindMed Insider Selling

Post published:May 30, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: CB Therapeutics’ Biosynthesis Patent; MindMed to Explore Mescaline; BBC Documentary Highlights Psilocybin

Psychedelic Bulletin: CB Therapeutics’ Biosynthesis Patent; MindMed to Explore Mescaline; BBC Documentary Highlights Psilocybin

Post published:May 22, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: MAPS Study Published in Nature Medicine; Numinus’ Hiring Spree; CB Therapeutics’ Series A

Psychedelic Bulletin: MAPS Study Published in Nature Medicine; Numinus’ Hiring Spree; CB Therapeutics’ Series A

Post published:May 14, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: MDMA Sees Success at Phase 3; MindMed Targets Pain; the Proliferation of Deuteration

Psychedelic Bulletin: MDMA Sees Success at Phase 3; MindMed Targets Pain; the Proliferation of Deuteration

Post published:May 8, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: MindMed Uplists to Nasdaq; Cybin Targets Alcoholism; COMPASS Announces $144m Offering

Psychedelic Bulletin: MindMed Uplists to Nasdaq; Cybin Targets Alcoholism; COMPASS Announces $144m Offering

Post published:April 30, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: MindMed to List on Nasdaq; Atai IPO Unveiled; Champignon Brands Resumes Trading

Psychedelic Bulletin: MindMed to List on Nasdaq; Atai IPO Unveiled; Champignon Brands Resumes Trading

Post published:April 23, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Experts Weigh in on Psilocybin vs. SSRIs; GH Research Closes $125m Round; California Decrim. Bill Passes 2nd Key Committee

Psychedelic Bulletin: Experts Weigh in on Psilocybin vs. SSRIs; GH Research Closes $125m Round; California Decrim. Bill Passes 2nd Key Committee

Post published:April 16, 2021
Post category:Psychedelic Bulletin

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.